Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Jennifer Diamond

Concepts (297)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Triple Negative Breast Neoplasms
16
2024
204
6.330
 Why?
Breast Neoplasms
25
2025
2294
4.300
 Why?
Immunoconjugates
7
2023
123
2.460
 Why?
Antineoplastic Agents
23
2023
2161
2.450
 Why?
Antineoplastic Combined Chemotherapy Protocols
20
2025
1748
2.400
 Why?
Pyrimidines
9
2021
476
2.280
 Why?
Receptor, ErbB-2
12
2025
355
2.040
 Why?
Protein Kinase Inhibitors
11
2025
914
1.800
 Why?
Piperazines
4
2020
349
1.610
 Why?
Paclitaxel
6
2022
237
1.540
 Why?
Camptothecin
9
2023
122
1.520
 Why?
Neoplasms
14
2022
2701
1.470
 Why?
Pyrazoles
6
2021
429
1.330
 Why?
Ovarian Neoplasms
5
2025
575
1.270
 Why?
Quinoxalines
2
2020
65
1.260
 Why?
Antibodies, Monoclonal, Humanized
10
2024
817
1.210
 Why?
Azepines
3
2020
97
1.200
 Why?
Histone Deacetylase Inhibitors
4
2024
208
1.160
 Why?
Cyclin-Dependent Kinase 4
2
2018
47
1.060
 Why?
Cyclin-Dependent Kinase 6
2
2018
42
1.050
 Why?
Neutropenia
4
2022
158
0.850
 Why?
Gene Expression Regulation, Neoplastic
5
2020
1388
0.750
 Why?
Xenograft Model Antitumor Assays
11
2021
865
0.720
 Why?
Breast Neoplasms, Male
2
2018
29
0.710
 Why?
beta Catenin
2
2020
252
0.710
 Why?
Female
52
2025
73913
0.670
 Why?
Chemotherapy, Adjuvant
4
2023
377
0.660
 Why?
Maximum Tolerated Dose
9
2022
204
0.660
 Why?
Benzoxazoles
1
2020
19
0.660
 Why?
Receptors, Estrogen
3
2021
440
0.650
 Why?
Cancer Care Facilities
1
2020
43
0.650
 Why?
Carcinoma, Lobular
2
2018
49
0.650
 Why?
eIF-2 Kinase
1
2019
32
0.620
 Why?
Lymphocytes, Tumor-Infiltrating
2
2020
206
0.620
 Why?
Tumor Microenvironment
4
2024
668
0.600
 Why?
Anthracyclines
3
2023
43
0.590
 Why?
Humans
65
2025
138651
0.590
 Why?
Taxoids
3
2023
101
0.580
 Why?
Aged
25
2025
24182
0.560
 Why?
Carcinoma, Ductal, Breast
1
2018
83
0.550
 Why?
Aurora Kinase A
4
2020
57
0.540
 Why?
Drug Resistance, Neoplasm
4
2020
800
0.540
 Why?
Wnt Signaling Pathway
1
2019
196
0.540
 Why?
Trastuzumab
4
2023
97
0.540
 Why?
Pyridines
3
2025
498
0.530
 Why?
Aromatase Inhibitors
3
2025
60
0.510
 Why?
Pyrazines
2
2018
88
0.510
 Why?
Colonic Neoplasms
1
2018
252
0.500
 Why?
Myocardial Infarction
1
2023
1069
0.490
 Why?
Tumor Suppressor Protein p53
4
2024
527
0.470
 Why?
Angiopoietin-1
1
2015
11
0.470
 Why?
Neoadjuvant Therapy
1
2018
409
0.470
 Why?
Angiopoietin-2
1
2015
15
0.470
 Why?
Neoplasm Recurrence, Local
5
2025
1065
0.460
 Why?
Nuclear Proteins
2
2023
708
0.460
 Why?
Medicare
4
2023
785
0.420
 Why?
Middle Aged
26
2025
33792
0.420
 Why?
Cell Line, Tumor
9
2022
3406
0.410
 Why?
Uterine Cervical Neoplasms
1
2017
290
0.410
 Why?
Colorectal Neoplasms
5
2022
803
0.400
 Why?
Adult
27
2025
38296
0.400
 Why?
Dose-Response Relationship, Drug
6
2022
2045
0.390
 Why?
Antibodies, Monoclonal
4
2024
1437
0.390
 Why?
Proto-Oncogene Proteins c-met
1
2013
73
0.390
 Why?
Tumor Suppressor Proteins
1
2015
324
0.390
 Why?
Cell Proliferation
8
2020
2474
0.380
 Why?
Treatment Outcome
13
2025
10938
0.380
 Why?
Recombinant Fusion Proteins
1
2015
662
0.380
 Why?
Antineoplastic Agents, Immunological
3
2019
191
0.380
 Why?
Point Mutation
1
2013
239
0.370
 Why?
Radiosurgery
3
2025
389
0.370
 Why?
Triazoles
1
2013
156
0.370
 Why?
Angiogenesis Inhibitors
3
2018
230
0.350
 Why?
Quinolines
3
2025
151
0.350
 Why?
Aged, 80 and over
10
2025
7683
0.340
 Why?
Mice, Nude
6
2020
689
0.340
 Why?
Carcinoma, Renal Cell
1
2013
212
0.330
 Why?
Clinical Trials, Phase I as Topic
2
2020
50
0.330
 Why?
Heart Failure
1
2023
2057
0.330
 Why?
Mitochondria
1
2017
958
0.330
 Why?
Histones
3
2023
637
0.320
 Why?
Genes, BRCA2
1
2009
31
0.320
 Why?
Neoplasm Metastasis
4
2020
668
0.320
 Why?
Genes, BRCA1
1
2009
41
0.320
 Why?
Biomarkers, Tumor
2
2014
1236
0.310
 Why?
Molecular Targeted Therapy
3
2019
414
0.300
 Why?
BRCA2 Protein
1
2009
63
0.300
 Why?
Pregnancy Complications, Neoplastic
1
2009
56
0.300
 Why?
Thrombophilia
1
2009
83
0.300
 Why?
Neoplasm Staging
5
2021
1376
0.290
 Why?
Kidney Neoplasms
1
2013
396
0.290
 Why?
Apoptosis
7
2024
2558
0.290
 Why?
Lung Neoplasms
2
2024
2531
0.290
 Why?
Receptors, Progesterone
2
2021
351
0.270
 Why?
DNA-Binding Proteins
1
2015
1476
0.270
 Why?
Models, Biological
1
2014
1815
0.250
 Why?
Mice
9
2021
17848
0.250
 Why?
Doxorubicin
3
2024
351
0.240
 Why?
Selective Estrogen Receptor Modulators
1
2025
32
0.240
 Why?
Cardiorespiratory Fitness
1
2025
57
0.230
 Why?
Cyclophosphamide
2
2018
254
0.210
 Why?
Disease Models, Animal
3
2021
4333
0.200
 Why?
United States
5
2023
15018
0.200
 Why?
Liver Neoplasms
1
2009
761
0.200
 Why?
Brain Neoplasms
3
2025
1268
0.190
 Why?
Biopsy
2
2018
1093
0.190
 Why?
Cyclin-Dependent Kinase 9
1
2022
10
0.190
 Why?
Animals
11
2021
37309
0.190
 Why?
Histone Deacetylase 1
1
2022
20
0.190
 Why?
Aurora Kinases
2
2012
28
0.180
 Why?
Administration, Oral
3
2022
789
0.180
 Why?
G2 Phase Cell Cycle Checkpoints
3
2022
44
0.180
 Why?
Topoisomerase I Inhibitors
2
2022
16
0.180
 Why?
Disease Progression
4
2019
2734
0.180
 Why?
Fluorouracil
1
2022
204
0.180
 Why?
Acetylation
1
2022
245
0.170
 Why?
Arrhythmias, Cardiac
1
2023
326
0.170
 Why?
Androstadienes
1
2021
78
0.170
 Why?
Biliary Tract Neoplasms
1
2021
29
0.170
 Why?
Diarrhea
2
2019
184
0.170
 Why?
Carboplatin
1
2021
146
0.170
 Why?
Heterografts
1
2021
134
0.170
 Why?
Drug Administration Schedule
3
2017
769
0.170
 Why?
Cancer Survivors
1
2025
289
0.170
 Why?
Hospitals, University
1
2021
179
0.170
 Why?
Necrosis
2
2019
247
0.170
 Why?
Histone Deacetylases
1
2022
210
0.160
 Why?
Fatigue
2
2022
337
0.160
 Why?
Mechanistic Target of Rapamycin Complex 2
1
2020
63
0.160
 Why?
Immunotherapy
2
2023
631
0.160
 Why?
Clinical Trials as Topic
3
2016
1033
0.160
 Why?
Immune System
1
2021
181
0.160
 Why?
Benzodiazepines
1
2021
154
0.160
 Why?
Male
13
2021
68216
0.160
 Why?
Myeloid Cell Leukemia Sequence 1 Protein
1
2019
41
0.150
 Why?
Mechanistic Target of Rapamycin Complex 1
1
2020
130
0.150
 Why?
Kaplan-Meier Estimate
1
2021
903
0.150
 Why?
Tumor Cells, Cultured
1
2020
949
0.150
 Why?
Albumins
1
2019
116
0.140
 Why?
Aquaporin 4
1
2019
97
0.140
 Why?
Maintenance Chemotherapy
1
2018
36
0.140
 Why?
Vascular Endothelial Growth Factor A
2
2018
551
0.140
 Why?
Aminopyridines
1
2018
103
0.140
 Why?
Nausea
1
2018
112
0.140
 Why?
Antibodies, Bispecific
1
2018
55
0.140
 Why?
Mice, Inbred BALB C
1
2020
1261
0.140
 Why?
Drug Therapy, Combination
1
2020
1048
0.140
 Why?
Breast
1
2018
158
0.140
 Why?
Radiotherapy, Adjuvant
1
2018
215
0.140
 Why?
Purines
1
2018
180
0.130
 Why?
Benzimidazoles
1
2018
175
0.130
 Why?
Topotecan
1
2017
13
0.130
 Why?
Mastectomy
1
2018
146
0.130
 Why?
Isoflavones
1
2017
26
0.130
 Why?
Calcium-Binding Proteins
1
2018
214
0.130
 Why?
Imidazoles
1
2018
240
0.130
 Why?
Survival Analysis
1
2020
1313
0.130
 Why?
Carbolines
1
2017
32
0.130
 Why?
Heterocyclic Compounds, 4 or More Rings
1
2017
20
0.130
 Why?
Programmed Cell Death 1 Receptor
1
2019
254
0.130
 Why?
Inhibitory Concentration 50
2
2016
89
0.130
 Why?
Retrospective Studies
4
2025
15860
0.120
 Why?
Neoplasms, Radiation-Induced
1
2016
93
0.120
 Why?
Hypertension
2
2018
1253
0.120
 Why?
Cell Survival
1
2019
1129
0.120
 Why?
Insulin-Like Growth Factor I
1
2018
324
0.120
 Why?
GPI-Linked Proteins
1
2016
76
0.120
 Why?
Neoplasms, Second Primary
1
2016
114
0.120
 Why?
Adaptor Proteins, Signal Transducing
1
2018
430
0.120
 Why?
Tumor Protein p73
1
2015
14
0.120
 Why?
Antibodies, Neoplasm
1
2015
34
0.120
 Why?
Nanoparticles
1
2021
468
0.120
 Why?
Carcinoma, Non-Small-Cell Lung
1
2024
1108
0.110
 Why?
Risk Reduction Behavior
1
2016
216
0.110
 Why?
Phosphorylation
1
2019
1770
0.110
 Why?
Hodgkin Disease
1
2016
156
0.110
 Why?
Maytansine
1
2014
17
0.110
 Why?
Demography
1
2015
296
0.110
 Why?
Brain Edema
1
2014
64
0.110
 Why?
Exercise
1
2025
2074
0.100
 Why?
Protein Kinases
1
2015
308
0.100
 Why?
Drug Interactions
1
2015
411
0.100
 Why?
Survival Rate
2
2019
1932
0.100
 Why?
Sulfones
1
2014
110
0.100
 Why?
Threonine
1
2013
47
0.100
 Why?
Randomized Controlled Trials as Topic
1
2019
1486
0.100
 Why?
Tumor Stem Cell Assay
1
2012
34
0.100
 Why?
Glycine
1
2014
176
0.100
 Why?
Drug Evaluation, Preclinical
1
2013
193
0.100
 Why?
Time Factors
2
2020
6877
0.100
 Why?
Drug Design
1
2013
165
0.100
 Why?
Methionine
1
2013
162
0.090
 Why?
Analgesics, Opioid
1
2021
1076
0.090
 Why?
Heterozygote
1
2013
305
0.090
 Why?
Disease-Free Survival
1
2014
704
0.090
 Why?
In Situ Hybridization, Fluorescence
1
2013
309
0.090
 Why?
Treatment Failure
1
2013
350
0.090
 Why?
Neovascularization, Pathologic
1
2013
296
0.090
 Why?
Cell Transformation, Neoplastic
1
2013
333
0.090
 Why?
Receptor Protein-Tyrosine Kinases
1
2013
231
0.090
 Why?
Carcinoma in Situ
1
2011
44
0.090
 Why?
Cluster Analysis
1
2012
515
0.090
 Why?
Diabetes Mellitus, Type 2
1
2025
2513
0.090
 Why?
Risk Assessment
1
2020
3459
0.090
 Why?
Computational Biology
1
2015
650
0.090
 Why?
Cellular Senescence
1
2012
190
0.080
 Why?
Vascular Endothelial Growth Factor Receptor-2
1
2010
86
0.080
 Why?
Risk Factors
2
2025
10398
0.080
 Why?
Colorado
1
2020
4528
0.080
 Why?
Sequence Analysis, DNA
1
2013
827
0.080
 Why?
Mutation
2
2012
3998
0.080
 Why?
Tumor Burden
1
2010
307
0.080
 Why?
Pregnancy Trimester, Second
1
2009
81
0.080
 Why?
Keratinocytes
1
2010
252
0.080
 Why?
Mastectomy, Segmental
1
2009
96
0.080
 Why?
Pregnancy Trimester, First
1
2009
137
0.070
 Why?
Apoptosis Regulatory Proteins
1
2009
191
0.070
 Why?
Lymph Node Excision
1
2009
168
0.070
 Why?
Poly(ADP-ribose) Polymerase Inhibitors
1
2009
116
0.070
 Why?
Risk
1
2009
912
0.070
 Why?
Infusions, Intravenous
2
2019
413
0.060
 Why?
Cell Adhesion Molecules
2
2019
177
0.060
 Why?
Prognosis
2
2018
4015
0.060
 Why?
Gene Expression Profiling
1
2012
1755
0.060
 Why?
Antigens, Neoplasm
2
2019
317
0.060
 Why?
Oxazoles
1
2025
37
0.060
 Why?
Cell Cycle Proteins
2
2023
615
0.060
 Why?
CD8-Positive T-Lymphocytes
2
2023
912
0.060
 Why?
Accelerometry
1
2025
109
0.060
 Why?
Cell Cycle
2
2018
598
0.050
 Why?
Combined Modality Therapy
2
2019
1237
0.050
 Why?
Quinazolines
1
2025
250
0.050
 Why?
Follow-Up Studies
2
2025
5160
0.050
 Why?
Mesylates
1
2022
6
0.050
 Why?
Ataxia Telangiectasia Mutated Proteins
1
2022
65
0.050
 Why?
Signal Transduction
2
2014
5091
0.050
 Why?
Oxygen Consumption
1
2025
708
0.050
 Why?
Clinical Protocols
1
2023
272
0.050
 Why?
Ligands
1
2024
665
0.050
 Why?
RNA, Small Interfering
1
2024
626
0.040
 Why?
Chimerism
1
2021
32
0.040
 Why?
Lymphocyte Subsets
1
2021
88
0.040
 Why?
Lymphoid Tissue
1
2021
79
0.040
 Why?
Liver
1
2009
1876
0.040
 Why?
Mice, SCID
1
2021
369
0.040
 Why?
Hormones
1
2020
142
0.040
 Why?
SEER Program
1
2021
220
0.040
 Why?
Mice, Inbred NOD
1
2021
596
0.040
 Why?
M Phase Cell Cycle Checkpoints
1
2018
24
0.040
 Why?
Tissue Distribution
1
2018
333
0.030
 Why?
Infant, Newborn
1
2009
6143
0.030
 Why?
Anemia
1
2019
175
0.030
 Why?
Insulin Resistance
1
2025
1225
0.030
 Why?
Pregnancy
1
2009
6836
0.030
 Why?
Cetuximab
1
2016
98
0.030
 Why?
Retreatment
1
2016
73
0.030
 Why?
Neoplasm Transplantation
1
2016
251
0.030
 Why?
Cyclin-Dependent Kinase Inhibitor p21
1
2016
121
0.030
 Why?
Drug Screening Assays, Antitumor
1
2016
193
0.030
 Why?
Platinum
1
2016
50
0.030
 Why?
Blood Glucose
1
2025
2190
0.030
 Why?
History, Ancient
1
2015
53
0.030
 Why?
Proto-Oncogene Proteins p21(ras)
1
2016
263
0.030
 Why?
Hematopoietic Stem Cell Transplantation
1
2021
661
0.030
 Why?
Transcription Factors
1
2023
1707
0.030
 Why?
Databases, Genetic
1
2015
241
0.030
 Why?
DNA Damage
1
2017
422
0.030
 Why?
Biomarkers
2
2016
4111
0.030
 Why?
Cross-Sectional Studies
1
2025
5523
0.030
 Why?
Mice, Knockout
1
2021
3038
0.030
 Why?
Quality of Life
1
2025
2954
0.030
 Why?
Opioid-Related Disorders
1
2021
541
0.020
 Why?
Phenotype
1
2021
3160
0.020
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2015
254
0.020
 Why?
Drug Combinations
1
2013
345
0.020
 Why?
Intracellular Signaling Peptides and Proteins
1
2015
463
0.020
 Why?
Immunohistochemistry
1
2016
1732
0.020
 Why?
Biopsy, Needle
1
2011
192
0.020
 Why?
Proto-Oncogene Proteins
1
2014
623
0.020
 Why?
HT29 Cells
1
2010
41
0.020
 Why?
Cohort Studies
1
2021
5729
0.020
 Why?
Transcription, Genetic
1
2017
1462
0.020
 Why?
Enzyme Inhibitors
1
2014
850
0.020
 Why?
Protein-Tyrosine Kinases
1
2013
431
0.020
 Why?
ErbB Receptors
1
2013
613
0.020
 Why?
Ki-67 Antigen
1
2010
110
0.020
 Why?
Capillary Permeability
1
2010
146
0.020
 Why?
Patient Selection
1
2013
692
0.020
 Why?
Patient Satisfaction
1
2013
679
0.020
 Why?
Positron-Emission Tomography
1
2010
302
0.020
 Why?
Membrane Proteins
1
2015
1153
0.020
 Why?
Algorithms
1
2015
1718
0.020
 Why?
Magnetic Resonance Imaging
1
2019
3642
0.020
 Why?
Tomography, X-Ray Computed
1
2016
2703
0.010
 Why?
Adolescent
1
2024
21528
0.010
 Why?
Brain
1
2014
2782
0.010
 Why?
Young Adult
1
2014
13322
0.010
 Why?
Diamond's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (297) concept(s)
_
Co-Authors Expand Description
See all (75) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)